Artiva Biotherapeutics Winds Down After Two Deaths in Phase 2 NK Cell Therapy Trial

Artiva’s trial used cord blood-derived NK cells with lymphodepleting chemotherapy preconditioning, standard for cell therapies to create space for engraftment. One death involved neurological complications attributed to the chemotherapy regimen rather than the NK cells themselves; a second patient died suddenly two months post-infusion with undetermined cause but deemed unrelated by investigators. The San Diego company cited these events as prompting the wind-down amid broader scrutiny of cell therapy safety signals.

This case echoes prior events in CAR-T and NK platforms where preconditioning regimens drive toxicity, as seen in early allogeneic trials reported in Blood and Nature Medicine. Autoimmune applications lack the malignancy burden of oncology yet inherit the same lymphodepletion risks, amplifying questions about net benefit when baseline mortality is lower. Observational data from small Phase 2 cohorts cannot isolate product versus procedure effects without matched controls.

Regulatory and investor response will likely accelerate requirements for enhanced monitoring protocols and larger safety databases before further autoimmune cell therapy advancement. Next studies must include randomized designs with explicit chemotherapy-attributable adverse event tracking and longer follow-up to quantify sudden death rates against disease-specific baselines.

Evidence here derives from company-reported trial outcomes without independent peer review or full dataset release; it can establish temporal associations but cannot prove causality or generalize across NK platforms. A subsequent multicenter RCT with adjudicated endpoints is required to clarify risk magnitude.